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Psoriasis has been studied intensively for
many years in an effort to understand the
cause and the mechanism(s) of this common
disease. Observations of the rate of scale
formation and the rate of healing after epi-
dermal removal have suggested that the in-
volved skin is engaged in rapid production of
epidermal cells. This feature of the psoriatic
plaque has been universally accepted regardless
of any etiologic theory, and has formed the
basis of all therapy—poisoning of the cellular
metabolism of the epidermis.
The quantitation of the proliferative abil-
ity of the epidermal cells in psoriasis has been
accomplished by Rothberg and Crounse (1)
who showed reduction of the transit time
from basal cell to shedding of stratum cor-
neum from the normal 27—30 days to the 3—4
days for the psoriatic epidermis. The biochem-
ical mechanisms by which a cell population
can so greatly increase its proliferative capac-
ity have been of general interest.
The processes of cellular metabolism are
controlled by enzymes or enzyme systems.
An understanding of these enzymatic systems
must precede a clear understanding of the
factors which control them. These enzyme
systems wifi also serve as a means to measure
changes in their control
Weber (2), Comiash (3), and Hasegawa (4)
have carried out enzymatic studies of the
normal appearing and involved epidermis of
patients with psoriasis. The changes in the
activity of one or a few isolated enzymes, how-
ever, are difficult to interpret and ignore the
changes which may be occurring in the levels
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of substrates and cofactors present within the
cells.
This report presents a survey of the en-
zymes, substrates, and co-factors involved in
epidermal glucose metabolism as measured
within the same tissue specimen both of the
diseased and normal appearing epidermis.
An attempt has been made in this work to
answer the following questions:
(1) Is there a lack or marked deficiency of
any enzyme in the epidermis (both involved
and non-involved) of patients with psoriasis?
Such a finding would point toward a gene di-
rected defect in the production of a particular
enzyme.
(2) Is there any difference between the en-
zyme and substrate levels of the normal ap-
pearing epidermis of patients with psoriasis and
the epidermis of normal people?
(3) What are the specific enzymatic changes
which allow increased epidermal proliferation
to proceed?
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Enzymes
ilK
PGM
PHI
UDPG PP
UDPG DII
Gly Syn
P-ase
G-6-P DH
6-P-G DII
PFK
ALD
GA-3-P DII
TIM
GDH
PGK
PGIyM
EN
PK
ME
LDII
hexokinase
phosphoglucomutase
phosphohexose isomerase
uridine diphosphoglucose pyro-
phosphorylase
uridine diphosphoglucose de-
hydrogenase
glycogen synthetase
phosphorylase
glucose-6-phosphate dehydro-
genase
6-phosphogluconate dehydro-
genase
phosphofructokinase
aldolase
glyceraldehyde -3-phosphate
dehydrogenase
triosephosphate isomerase
glycerol-i-phosphate dehydro-
genase
3-phosphoglycerate kinase
phosphoglycerate mutase
enolase
pyruvic kinase
malic enzyme
lactate dehydrogenase
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ethylenediaminetetraacetate
tris (hydroxymethyl)amino
methane
inorganic phosphate
adenosine triphosphate
adenosine diphosphate
uridine triphosphate
uridine diphosphate
nicotinamide-adenine -dinucle-
otide (oxidized) (diphospho-
pyridine nucleotide (oxi-
dized)
nicotinamide-adenine -dinucle-
otide (reduced) (diphospho-
pyridine nucleotide (re-
duced)
nicotinamide- adenine-dinucle-
otide phosphate (oxidized)
(triphosphopyridine nucleo-
tide (oxidized)
nicotinamide-adenine -dinucle-
otide phosphate (reduced)
(triphosphopyridine nucleo-
tide (reduced)
that amount of enzyme which
will "turn over" 1 micromole
of substrate in 1 minute at
25° C.
EXPERIMENTAL
Subjects
Twelve patients with psoriasis served as sub-
jects. Epidermal strips, approximately 1 inch x 4
inches x 02 mm thick, were removed with a Cas-
troviejo keratome. Psoriatic lesions were chosen
which had adjacent uninvolved skin to serve as
the control. If possible, four epidermal strips were
removed Ironi each patient; two from an involved
area and two from the adjacent non-involved area.
METHODS
Tissue Preparation
One epidermal strip from each area was frozen
in liquid N2 within 5 seconds after removal to stop
all enzyme action. Each frozen strip of epidermis
was weighed, then homogenized in 0.6 N perchiorie
acid (100 mg of epidermis/i cc of acid) for 30
seconds to precipitate all proteins. The perchloric
acid extract was neutralized with 2 N potassium
hydroxide and used for the substrate assays. This
extract is hereafter referred to as the "acid ex-
tract."
The second epidermal strip from each area was
divided into two parts. The smaller piece was
fixed in Helley's solution for histological examina-
tion. The larger remainder was weighed, then ho-
mogenized for 30 seconds at 0° C. in 0.05 M "tris"
buffer (pH 7.4) which contained 0.003 M MgC12
and 0.0005 M EDTA (100 mg of epidermis/i cc of
buffer). This preparation was used for enzyme as-
says and is referred to as the "epidermal homoge-
nate."
Histology
Histologic sections were cut at 6 and stained
with H and E, PAS, and PAS controlled by cia-
stase. These sections were evaluated for the fol-
lowing:(1) total depth of slice
(2) depth of stratum corneum and percentage
of parakeratotic cells in the stratum cor—
neum.
(3) thickness and extent of stratum granulosum
(4) number of suprapapillary cell layers
(5) total cell layers, and
(6) amount and distribution of glycogen.
In addition, the number of malpighian cells fitting
within a calibrated square (361 2) was estimated
at several places on each specimen and from this
an estimate of the approximate individual cell
volume was made assuming the cell to be cuboidal.
Biochemistry
Reference 5 contains a detailed account of the
fluorometric method used for all the analyses with
the exception of the phosphate determination (6).
This method depends on the fluorescent properties
of NADH (DPNH) and NADPH (TPNH). These
nucleotides fluoresce at approximately 460 m
when irradiated by light of 340 m. The amount
of fluorescence is directly proportional to the
amount of nucleotide present in the solution. The
oxidized forms of these compounds neither absorb
at 340 m nor fluoresce at 460 m.
These nucleotides are essential co-factors in
many enzymatic reactions involving the transfer
of hydrogen. Any reaction sequence which can be
arranged to finally cause an increase or decrease
in the amount of NADH or NADPH present in
the reaction tube can be easily quantitated by this
method. Details of the individual assays follow.
(Figure 1 is a metabolic chart showing the posi-
tions of all the enzymes and substrates for refer-
ence.)
Enzyme Assays
Tables I and II list the ingredients necessary
for carrying out the various assays. The assays for
Enzymes—Continued
MDH
ICDH
Substrates
G-1-P
G-6-P
IJDPG
6-PG
F-6-P
F-i, 6 diP
PEP
DHAP
malate dehydrogenase
isocitrate dehydrogenase
glucose-i-phosphate
glucose-6-phosphate
uridine diphosphoglucose
6-phosphogluconate
fructose-6-phosphate
fructose-i, 6-diphosphate
phosphoenolpyruvate
dihydroxyacetone phosphate
Cof actors & Miscellaneous
EDTA
"TRIS"
P045-
ATP
ADP
UTP
UDP
NAD (DPN)
NADH (DPNH)
NADP (TPN)
NADPH (TPNH)
1 enzyme unit
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Fia. 1. Metabolic map. Reactions where changes in coenzymes participate are also shown
hexokinase, glucose-6-P dehydrogenase, phospho-
glucomutase, uridine diphosphoglucose pyrophos-
phorylase, uridine diphosphoglucose dehydrogen-
ase, glycogen synthetase, and phosphorylase are
discussed in reference 5.
6-phosphogluconate dehydrogenase (8-PG DH)
is assayed by adding 10 d (equivalent to 1 mg of
epidermis) of homogenate to 1 cc of "tris" buffer
containing 0.1 sm of NADP and 0.7 m of 6-phos-
phogluconate. 6-PG DII present in the homogenate
will oxidize the 6-PG to ribulose-5-P with the si-
multaneous reduction of NADP to NADPII. This
formation of NADPH is recorded and the rate of
its formation is a direct measure of the amount of
6-PG DII present in the homogenate.
Phosphohexose isomerase (PHI) is assayed by
adding 10 d of homogenate to 1 cc of "tris" buffer
containing NADP (0.1 gm), glucose-6-phosphate
dehydrogenase (G-6-P DII) (0.1 ), and fructose-
6-phosphate (F-6-P) (0.7 sm). The PHI in the
homogenate converts F-6-P to G-6-P. The excess
of G-6-P DII in the reaction mixture oxidizes the
G-6-P to 6-PG with the simultaneous reduction of
NADP to NADPH. In this case the rate of for-
mation of NADPH is a measure of the amount of
PHI present in the homogenate.
Phosphofructokinase (PFK) is assayed by add-
ing 10 l of homogenate to 1 cc of tris buffer con-
taining the substances checked under the appro-
priate column in table 1. In the presence of PFK,
fructose-6-phosphate (F-6-P) combines with ATP
to produce fructose-i ,6-diphosphate (Fl ,6-diP)
and ADP, Aldolase (ALD) and triosephophate
isomerase (TIM) combine to convert the F1,6-
diP to dihydroxyacetone phosphate (DHAP).
DHAP is reduced in the presence of glycerol-i-
phosphate dehydrogenase (GDH) to glycerol-i-
phosphate with the simultaneous oxidation of
NADH. The rate of disappearance of the fluores-
cence due to NADH is then a measure of the
PFK in the homogenate.
Aldolase (ALD) is assayed by measuring the
rate of breakdown of Fl, 6-diP in the presence of
homogenate. The glyceraldehyde-3-phosphate and
DHAP formed by this reaction is all converted
to DHAP by TIM and the DHAP is reduced by
GDH and NADH as in the preceding example. In
this case, however, the rate of reduction of the
fluorescence is a measure of ALD rather than of
PFK.
Triose phosphate isomerase (TIM) is assayed
by measuring the rate of formation of DIIAP from
glyceraldehyde-3-phosphate in the presence of ho-
mogenate. The DHAP formed is converted to
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TABLE I
Methods for enzyme assays
The enzyme assayed for is on the top line while the compounds added to the reaction mixture are
along the left hand column. See text.
Reaction Mixture
1 cc tris buffers
lOpl hoogenate
additions as Checked
Enzyme Being Assayed
—
HE G-6-P 6-P-G PGM UDPG tJDPG phoryl- PHI PFK ALD
ase
Glucose (0.55 pm) X
ATP(0.7pm) X x
G-6-P DII (0.1 u) X X X X
NADP (0.1 pm) X X X X x x
G-6-P (0.7 pm) X x
6-P-G (0.7 pm) X
G-1-P (0.7 pm) X X
UTP (0.7 pm) x
UDPG DII (0.9 u) X
NAD(0.5pm) X X
UDPG (0.25 pm) x x
Glycogen (1.5 mg) x x
PEP (1.0 pm) x
PK (0.48 u) X
LDH(0.5u) X
NADII (0.1 pm) X X X
AMP (0.7 pm) X
PO4 (1.0 urn) X
PGM (0.5 U) x
F-6-P (0.7 pm) x x
ALD (0.5 u) x
TrM(6.Ou) x x
GDH (2.0 u) x x
F-1,6 di P (0.7 pm) X
* Tris buffer 0.05 M pH 7.4 containing 0.003 M MgClz and 0.0005 M EDTA.
glycerol-i-phosphate by GDH as in the preceding
example and the rate of disappearance of fluores-
cence of NADH is followed.
Glycerol-i-phosphate dehydrogenase (GDH) is
assayed by following the rate of disappearance of
DIIAP in the presence of homogenate and NADH.
The simultaneous oxidation of NADU results in a
disappearance of its fluorescence which is quan-
titated. The DRAP is generated by adding glycer-
aldehyde-3-phosphate and TIM to the reaction
mixture.
Glyceraldehyde -3-phosphate dehydrogenase
(GA-3-P DH) is assayed by measuring the rate
of formation of 1: 3-diphosphoglycerate from glyc-
eraldehyde-3-P in the presence of NAD and ho-
mogenate. NAD is reduced to NADH during this
reaction and the rate of NADU formation is a
measure of the GA-3-P DII in the homogenate.
3-phosphoglyceate kinase (PGK) is assayed by
measuring the rate of formation of 1, 3-diphospho-
glycerate from 3-phosphoglycerate in the presence
of homogenate and ATP. i,3-diphosphoglycerate
formation is followed by adding excess GA3P DII
and NADU. Any 1 ,3-diphosphoglycerate formed
is immediately reduced by GA3P DII to glycer-
aldehyde-3 phosphate with the simultaneous oxi-
dation of NADH. The rate of disappearance of
the fluorescence of NADU is measured.
Phosphoglycerate mutase (PGZyM) is assayed
by measuring the rate of formation of 2-phospho-
glycerate from 3-phosphoglycerate in the presence
of homogenate. The formation of 2-phosphoglyc-
erate is followed by converting it to phosphoenol-
pyruvate (PEP) with excess enolase (EN). In the
presence of KC1, ADP, and pyruvic kinase (PK),
PEP is converted to pyruvate. The pyruvate, in
turn, is reduced to lactate by added lactate de-
hydrogenase (LDH) with NADH serving as a
hydrogen donor. The disappearance of NADH
fluorescence is actually measured.
Enolase (EN) is assayed by measuring the rate
of formation of phosphoenolpyruvate (PEP) from
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TABLE II
Methods for enzyme assays. (cong.)
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Reaction Mixture
lcctrisbuffer
+
Enzyme ]3eing Assayed
—
10 ,a homogenate
additions as checked
GDH GASP PGK PGIyM EN PK LDH MDII ICDH ME
ATP (O.7.uni) x
TIM (6.0 u) X
GDH (2.0 u) X
NADU (0.1 pm) X X X X X X X X
Glyceraldehyde-3-P (0.7 X X X
pm)
NAD (0.5 pm) X
3-P-Glycerate (0.7 pm) X X X
GA3P DII (1.2 p) X
EN (0.5 u) X
PK(1.5u) X X
KC1 (1.0 pm) X X X
ADP (l.Opm) X X X
LDH(0.5u) X X X
PGM (0.5 u) X
Pyruvate (0.5 pm) X
Phosphoenolpyruvate (0.5 x
jzm)
Oxaloacetate (0.5 pm) X
NADP(0.lpm) X X
Isocitrate (0.7 urn) X
Malate (0.7 pm) X
* Tris buffer 0.05 M pH 7.4 containing 0.003 M MgC12 and 0.0005 M EDTA.
2-phosphoglycerate in the presence of homogenate.
The 2-phosphoglycerate is generated from 3-phos-
phoglycerate by the addition of PG1yM. PEP
formation is followed by its conversion to pyru-
vate and subsequent assay with LDH as in the
preceding example.
Pyruvic kinase (PK) is assayed by measur-
ing the rate of formation of pyruvate from PEP in
the presence of homogenate. As indicated in the
preceding example KCI and ADP are necessary for
this reaction and the pyruvate so formed is then
measured using LDH and NADH.
Lactate dehydrogenase (LDH) is assayed by
measuring the rate of formation of lactate from
pyruvate in the presence of homogenate. NADII
is oxidized during this reaction and the rate of its
disappearance serves as an indicator.
Malate dehydrogenase (MDH) is assayed by
measuring the rate of formation of malate from
oxaloacetate (OAA) in the presence of homoge-
nate. NADH serves as hydrogen donor and the
rate of its disappearance is recorded.
Isocitrate dehydrogena.se (ICDH) is assayed by
measuring the rate of oxidation of isocitrate in
the presence of NADP and homogenate. NADP
serves as hydrogen acceptor and the rate of for-
mation of NADPH is recorded.
Malic enzyme (ME) is assayed by measuring
the rate of oxidation of malate in the presence of
NADP and homogenate. The formation of
NADPH is followed. By the use of LDH and
NADII it has been verified that the product of
the malic enzyme reaction is actually pyruvate.
Substrates
Tables III and IV list the reaction mixtures
used for these assays. Specific details of glucose,
G-6-P, G-1-P, UDPG, Glycogen, and ATP have
been given in reference 5. Details of the other as-
says are as follows:
Fructose-6-phosphate (F-6-P) is assayed by
adding 10 p1 of "acid extract" (equivalent to 1 mg
of epidermis) to 1 cc of buffer containing excess
PHI, G-6-P DH and NADP. The F-S-P is con-
verted to G-6-P by PHI. G-6-P is converted to
6-PG by G-6-P DII providing NADP is present
as a hydrogen acceptor. For every molecule of
6-P-G formed one molecule of NADP will be re-
duced to NADPH. The total amount of NADPH
TABLE III
Methods for substrate assays
Reaction Mixture
1 cc tris buffer*
+
10 pl "acid extract"
additions as checked
Substrate Being Assayed
Glucose G-6-P G-1-P F-6-P 6-P-G UDPG Glyco- DHAP G-A-3P NAD NADP
NADP(0.lpm)
G-6-P DII (0.7 u)
ATP (0.7 pm)
HK (0.7 u)
PGM(0.5u)
PHI (0.7 u)
6-P-GDH (0.5 u)
UDPG DII (0.9 u)
WAD (0.5 pm)
Phosphorylase (1.4 u)
AMP (0.lpm)
PO4 (1.0 pm)
NADII (0.02 pm)
GDH.(2.Ou)
TIM (6.0 u)
ALD (0.5 u)
Glycine-IIydrazine 1
cc buffer pH 9.4
G-6-P (0.7 pm)
Lactate (1.0 pm)
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
x
x
X
x
* Tris buffer 0.05 M pH 7.4 containing 0.003 M MgC12 and 0.005 M EDTA. Not used when assaying
for NAD.
TABLE IV
Methods for substrate assays. (cont.)
Reaction Mixture
1 cc tris buffer*
10.
"aci extract"
additions as checked
Substrate Being Assayed
gee
20 pl
glyeete
20 pl
glyc'ate
20 pl
Pyruvate Lactate tie Isocitrate ATP ADP
NADH (0.02 urn)
Ga3-P DII (1.2 u)
ATP (0.7 urn)
PGK (0.5u)
PG1yM (0.5 u)
EN (0.5 u)
LDH (0.5 u)
Hydrazine-glycine
buffer pH 9.4 (1 cc)
NAD (0.28 pm)
MDII (0.10 u)
NADP (0.12 pm)
ICDH (0.35 u)
Glucose (0.55 pm)
ilK (0.7 u)
G-6-P DII (0.7 u)
PK (1.5 u)
PEP (0.5 pm)
KC1 (1.0 pm)
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
x
X
x
X
X
X
X
x
x
* Tris buffer 0.05 M pH 7.4 containing 0.003 M MgC12 + 0.0005 M EDTA except for lactate assay.
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formed is then a direct measure of the amount of
F-6-P originally in the "acid extract."
6-phosphogluconate (6-PG) is assayed by con-
verting it to ribulose-5-phosphate in the presence
of 6-PG DR and NADP. The amount of NADPH
formed is a direct measure of the amount of 6-PG.
Dehydroxyacetone phosphate (DHAP) is as-
sayed by its reduction to glycerol-i-phosphate by
GDH. The hydrogen donor for this reaction is
NADII and the total decrease in amount of
NADH is a measure of the DRAP originally pres-
ent.
Glyceraldehyde-S-phosphate (GA3P) is assayed
by adding TIM after the preceding reaction has
stopped. Any GA3P in the solution will then be
converted to DHAP which will cause a further
consumption of NADH as in the preceding reac-
tion.
Fructose 1,6 diphosphate (Fl,6-diP) is assayed
by adding ALD after the preceding reaction has
been completed. This enzyme converts F1,6-diP
to GA3P and DHAP while the TIM assures that
the GA3P will also be converted to DHAP. The
DHAP is reduced by NADH, and a further de-
crease in the amount of NADH equal to 2 times
the amount of Fi,6-diP is recorded.
Nicotinamide adenine dinucleotide (NAD) is
assayed by converting it to NADH in the pres-
ence of lactate and LDH. It should be noted that
this reaction requires a special buffer and high pH
since at lower pH the reaction is strongly in the
reverse direction.
Nicotinamide adenine dinucleotide phosphate
(NADP) is assayed by converting it to NADPH
in the presence of G-6-P and G-6-PDH.
1 ,3-diphosphoglycerate is assayed by convert-
ing it to glyceraldehyde-3P using GA3PDH.
NADH serves as hydrogen donor and is converted
to an equal amount of NAD and can be quanti-
tated.
3-phosphoglycerate is assayed by adding ATP
and phosphoglycerate kinase (PGK) after the pre-
ceding reaction has stopped. All the 3-phospho-
glycerate will be converted to 1, 3-diphosphoglyc-
erate which will cause a further decrease in NADH
fluorescence.
2-phosphoglycerate is assayed by adding phos-
phoglycerate mutase (PG1yM) after the preceding
reaction has stopped. 2-phosphoglycerate in the
"acid extract" will be converted to 3-phosphoglyc-
erate which as in the preceding will again give rise
to a decrease in the NADH fluorescence.
Phosphoenolpyruvate (PEP) is assayed by con-
verting it to 2-phosphoglycerate by the use of
enolase (EN). Further reactions are as above.
Pyruvate is assayed by converting it to lactate
in the presence of LDH and NADH. The NADH
serves as a hydrogen donor and the decrease in
fluorescence is observed.
Lactate is assayed by reversal of the previous
reaction at high pH in hydrazine-glycine buffer.
NADH formation from NAD is observed as the
lactate present in the "acid extract" is converted
to pyruvate by LDH.
Oxaloacetate (OAA) is assayed by converting
it to malate by the use of MDH. NADH serves
as hydrogen donor, and the decrease of the com-
pound is measured.
Isocit rate (IC) is assayed by oxidation using
NADP and isocitric dehydrogenase (ICDH). The
formation of NADPH is measured.
Adenosine triphosphate (ATP) assay is dis-
cussed in reference 5.
Adenosine diphosphate (ADP) is assayed by
converting it to ATP in the presence of PEP and
PK. During this process PEP is converted to py-
ruvate which is then assayed by the use of LDH
and NADH.
RESULTS
Table V lists the patients used in the study.
In one instance (Mrs. J.) the strips of normal
and involved epidermis were not taken from
adjacent areas.
Tables VI, VII, and VIII list the results of
the enzyme assays. The assays were performed
at room temperature.
Tables IX and X list the results of the sub-
strate and co-factor assays. The most signifi-.
cant finding here is the three fold increase in
the glycogen content of the psoriatic plaque.
Table XI lists the histological findings. In
general, the PAS technic for glycogen corre-
sponds with the biochemical findings. The
malpighian cells of the psoriatic plaque are
uniformly larger than the cells in the neigh-
boring normal appearing epidermis.
DISCUSSION
In the introduction to this study we posed
three questions which we should now like to
discuss:
(1) Are there any enzyme deletions or gross
reductions in enzyme activities in the psoriatic
epidermis?
All of the enzymes assayed could be dem-
onstrated in both the normal-appearing and
involved epidermis of patients with psoriasis.
Furthermore, with the exception of phospho-
rylase all activities were increased in the pso-
riatic plaque and are therefore responsive to the
needs of the cell. We conclude from this that
there is no demonstrable genetic defect in the
production of these enzymes.
(2) Is the normal appearing epidermis of
patients with psoriasis biochemically equivalent
to the epidermis of normal people?
With the exception of a possible decrease in
the ability to form cholesterol esters (7), there
is no evidence to our knowledge of any bio-
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TABLE V
Clinical data on each patient
Name Sex Race Age Area Comments
Mrs. W. F W 78 Back Moderate psoriasis—no Rx.
Mrs. H. F W 70 Thigh Moderate psoriasis—no Rx.
Mr. I. M W 48 Shoulder Mild psoriasis almost healed with only residual dis-
coloration. Tar and U. V. L. Rx.
Mr. S. M W 46 Leg Mild psoriasis—no Rx.
Mrs. J. F W 60 Lumbar Moderate psoriasis "normal" appearing skin from
thigh. 'Plaque" from lumbar area. No Rx. for 3
weeks.
Mr. C. M W 25 Thigh Mild psoriasis—no Rx.
Mrs. B. F W 22 Back Psoriasis involving only hands, nails, elbows and
knees.
Mr. B. M W 65 Back Severe psoriasis (70% of body)—no Rx.
Mr. M. M W 61 Back Severe psoriasis (80% of body)—no Rx.
Mrs. S. F W 80 Lumbar Mild psoriasis—has used ammoniated mercury and
tar intermittently.
Mr. M. M W 30 Thigh Mild psoriasis—no Rx for 1 month.
Mrs. V. F N 32 Leg Using "Tegrin" only.
TABLE VI
Results of individual enzyme assays on each patient
All reactions carried out at room temperature (25° C.) and pH 7.4. All results given in mum of sub-
strate "turned over"/min/milligram of epidermis (fresh).
Mrs. W. Mrs. H. Mr. I. Mr. S. Mrs. J. Mr. C.
Enzyme ____
PN P N P N N P N P N P
UK 1.03 1.75 <0.01 0.73 1.05 0.97 0.35 0.70 1.50 2.56 1.35 1.70
PGM 0.50 1.30 0.10 2.33 1.27 1.07 0.32 0.80 0.55 1.76 0.90 0.95
UDPG PP 0.56 0.67 0.75 0.76 0.50 0.59 0.13 0.25 0.32 0.48 0.22 0.30
UDPG DII 0.04 0.05 <0.01 0.02 <0.01 <0.01 <0.01 <0.01 <0.01 0.03 <0.01 0.03
GlySyn 0.17 0.33 0.11 0.17 0.27 0.33 0.08 0.10 0.10 0.11 0.10 0.11
P-ase 0.32 0.33 0.06 0.20 0.23 0.13 0.07 0.05 0.27 0.32 0.40 0.25
PHI 25.5 24.0
PFK
ALD 0.17 1.85 0.39 0.92 <0.01 0.06 <0.01 4.80
TIM
GDH
GA3P DII 0.50 5.00 9.20 13.4 0.34 0.56 5.5024.0 4.00 5.00
PGK
P Gly M
EN
PK
LDII 38.3 103 7.30 19.3 5.7 17.5 3.50 8.70 13.0 100 30.0 60.0
ME
MDH 43.3 108 7.30 17.3 6.7 10.0 3.50 8.80 11.7 53.3 23.3 48.3
ICDH 0.50 0.80 <0.01 1.37 1.33 1.73 0.56 1.03 1.15 1.36 1.50 1.25
G-6-PDH 0.55 3.83 <0.01 4.73 1.00 2.53 0.37 2.50 1.20 5.04 1.15 5.50
6-P-GDH 0.17 0.93 <0.01 2.10 0.25 0.55 0.17 0.65 0.37 1.45 0.27 1.10
TABLE VII
Results of individual enzyme assays on each patient. (cont.)
Enzyme
Mrs. B. Mr. B. Mr. M. Mrs. S. Mr. Mi. Mrs. V.
OnlyN N P N P N P N P N P
ilK
PGM
UDPGPP
UDPG DII
GlySyn
P-ase
PHI
PFK
ALD
TIM
GDII
GA3PDH
PGK
PG1yM
EN
PK
LDH
ME
MDII
ICDII
G-6-P DII
6-PGDII
1.60
0.72
0.05
0.13
0.27
7.70
1.60
0.27
19.7
0.46
43.3
37.3
1.20
1.04
0.27
1.71
1.36
0.16
0.03
0.05
0.32
12.2
0.15
1.44
0.07
11.2
0.27
53.3
28.6
1.04
2.72
0.80
1.84
1.20
0.24
0.03
0.08
0.24
16.0
0.48
2.08
0.16
18.7
1.07
101
68.8
0.48
6.00
1.60
2.24
1.60
0.37
0.02
0.05
0.32
19.2
0.68
1.12
117
0.27
8.3
11.2
27.2
16.0
1.12
53.3
0.16
53.3
1.39
1.52
0.67
2.56
2.08
0.37
0.03
0.08
0.48
41.6
1.60
2.24
149
0.27
13.6
16.0
37.2
21.3
1.12
80.0
0.25
80.0
1.20
4.80
1.12
0.16
<0.01
0.24
<0.01
0.01
0.12
11.7
0.24
0.40
124
0.32
0.48
0.48
10.7
7.5
0.16
31.0
0.08
26.0
<0.01
<0.01
<0.01
0.16
0.37
0.24
0.02
0.03
0.16
15.5
0.27
1.04
201
0.32
6.40
3.72
14.4
12.3
0.16
49.6
0.35
49.6
<0.01
1.36
<0.01
1.28
0.48
0.48
.016
.053
0.40
17.0
0.48
1.04
168
0.16
12.8
27.2
16.0
11.2
1.12
48.0
0.16
38.2
1.04
0.96
0.24
1.76
0.48
0.56
.032
.096
0.27
24.0
0.56
2.64
235
0.48
17.6
27.2
22.4
22.4
1.12
68.8
0.34
48.0
1.12
2.88
0.53
0.88
0.64
0.55
0.03
.133
.189
20.8
0.11
0.32
171
<0.10
5.28
12.8
16.0
8.00
0.64
38.4
.144
32.0
0.88
0.64
0.18
1.52
0.96
0.69
0.04
.222
.297
33.6
0.80
1.12
307
0.11
12.3
24.0
24.0
20.8
0.96
77.3
.213
60.8
1.12
2.56
0.53
TABLE VIII
Results of individual enzyme assays. Summary of group range and averages
Enzyme
Range Average th S.D.
%N—.PIncrease SignificanceP Value
N P N P
ilK (11)*
PGM (11)
UDPGPP (11)
UDPG DII (11)
GlySyn (11)
P-ase (11)
Pill (6)
PFK (5)
ALD (9)
TIM (4)
GDH (5)
GA3P DII (5)
PGK (4)
P G1yM (4)
EN (4)
PK (5)
LDH (11)
ME (4)
MDII (11)
ICDH (11)
G-6-PDH (11)
6-P-GDH (11)
<0.01—2.24
<0.01—1.60
0.13—0.75
<0.01—0.04
0.01—0.27
0.06—0.40
11.7—25.5
0.11—0.68
<0.01—1.44
117—171
<0.10—0.32
0.5—12.8
0.5—27.2
10.7—27.2
7.5—16.0
0.16—1.12
3.5—53.3
0.08—0.16
3.5—53.3
<0.01—1.50
<0.01—2.72
<0.01-0.80
0.16—2.56
0.37—2.33
0.24—0.76
<0.01—0.05
0.03—0.33
0.05—0.48
15.5—41.6
0.27—1.60
0.06-4.80
149—307
0.11—0.48
6.4—18.7
3.7—27.2
14.4—37.2
12.3—22.4
0.16—1.12
8.7—103.0
0.21—0.35
8.8—108.0
<0.01—1.73
1.36—6.00
<0.01—2.10
1.05 0.52
0.70 0.39
0.39 0.16
.018 .010
0.10 0.05
0.25 0.10
17.7 4.1
0.33 0.20
0.54 0.44
145 25
0.18 0.09
7.6 3.8
12.9 7.1
17.5 4.9
10.7 2.9
0.66 0.37
29.3 15.9
0.14 0.03
24.9 14.0
0.86 0.43
0.92 0.55
0.29 0.18
1.48 0.61
1.21 0.48
0.47 0.17
.027 .009
0.15 0.08
0.27 0.09
25.8 7.9
0.74 0.37
1.84 0.96
223 48
0.27 0.11
13.7 3.5
17.7 7.9
24.5 6.4
19.2 3.5
0.89 0.29
62.3 28.4
0.29 0.06
50.3 21.7
1.04 0.34
3.79 1.29
0.96 0.47
41
73
21
50
50
8
45
124
241
54
50
80
37
40
80
35
113
107
102
21
312
231
<.001
<.001
<.001
<.01
<.01
>01
<0.1
<0.1
<.01
<.05
>0.1
<.01
<.02
<.02
<.02
>0.1
<.01
<.05
<.01
>0.1
<.001
<.001
* Number of patients assayed.
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TABLE X
Results of individual substrate assays. Summary of group and averages
Substrate or Cofactor
Range Average S.D. :&
N P N P
Glucose (7) 0.10—1.60 0.10—1.39 0.82 0.40 0.79 0.31 ,J.4%
UDPG (7) .045—.120 .063—.l00 .075 .016 .090 0.011 120%
Glycogen (7) *260-670
fl.44—3.72
640—.4360
3.55—24.2
480 126
2.66 0.70
1814 1068
10.1 5.93
1280%
Fructose 1,6 diP (6) .075—.152 .060—.115 .118 .017 .084 .016 20%
Pyruvate (6) 0.10-0.30 0.16—0.50 0.22 0.06 0.26 0.07 118%
Lactate (6) 5.00—10.00 4.00—13.00 7.05 1.13 7.82 3.39 111%
DPN (6) .075—.200 .100—.250 .133 .042 .142 .056 17%
ATP (6) .200—.430 .160—.630 .318 .075 .401 .126 126%
ADP (7) 0.72—1.40 0.48—1.40 1.14 0.21 1.08 0.31 5%
PO4 (7) 6.5—28.0 9.0—25.0 12.6 5.81 13.4 4.4 16%
* millimicrograms/mg.
f mum/mg (glucose equivalents).
chemical difference between the normal appear-
ing epidermis of patients with psoriasis and
the epidermis of normal people. Table XII
lists our available assays on normal epidermis
from 20—25 year old male adults and from two
normal adults of an age more comparable with
our psoriasis group.
There are no striking differences enzymati-
cally between the normal appearing epidermis
of patients with psoriasis and normal epider-
mis. Comaish (3) in his study of aldolase ac-
tivity came to the same conclusion for that par-
ticular enzyme.
(3) What are the specific enzymatic changes
which characterize the transitions from the
normal appearing epidermis to the psoriatic
plaque?
These enzyme changes are shown graphically
in Figure 2 which is a simplified version of
the metabolic chart. The width of the arrow
corresponds to the % increase in activity of a
particular enzyme when the normal appearing
skin is compared with the neighboring psoriatic
plaque. The single black line as shown for the
breakdown of glycogen to glucose-i-phosphate
represents no change. Each stripe in the arrow
represents an increase in activity of approxi-
mately 25%. In no instance was the activity of
an enzyme in the psoriatic plaque less than the
activity of the same enzyme in the neighboring
normal appearing epidermis.
The chart shows that the reorganization of
cellular metabolism necessary to sustain the in-
creased rate of proliferation in the psoriatic
plaque occurs not by increasing the concentra-
tion of one or a few key enzymatic steps, but
by increasing each of the enzymes responsible
for a whole series of reactions. These changes
will be discussed along with the substrate and
cofactor concentrations in more detail under the
following headings:
(a) The utilization of glucose
(b) The utilization of glucose-6-phosphate
(e) The utilization of glucose-i-phosphate to
form glycogen and uronic acids
(d) The formation of pentose sugars (the
hexose monophosphate shunt)
(e) The utilization of fructose-6-phosphate
and the formation of triose phosphate
(f) Pyruvate formation and utilization
(g) The tricarboxylic acid cycle (Krebs cycle)
and oxygen utilization
(h) The role of the co-factors
(i) Lactate production
(j) Histological data
(a) The Utilization of Glucose
The activity of HK was increased 40% in
the psoriatic plaque. In addition, the concen-
tration of ADP (Table X) is decreased while
the level of ATP is increased. These sub-
strate changes should result in even greater
utilization of glucose than is indicated by the
enzyme change itself since ADP is a potent in-
hibitor of hexokinase while ATP is one of the
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substrates for the enzyme (8). Increased
glucose utilization in psoriatic lesions has also
been shown by Herdenstam (9).
Glucose values ranged from 0.1—1.6 mm/
mg of tissue and did not exhibit any consistent
pattern.
(b) The Utilization of Glucose-C-phosphate
Glucose-6-phosphate (formed by hexokinase)
was utilized immediately and did not accumu-
late. PHI, PGM, and G-6-P DII, and probably
glucose-6-phosphatase (not shown) all com-
pete for the available G-6-P. Frienkel reported
that in normal epidermis about 80% of G-6-P
was converted to F-6-P and about 5% was con-
verted to 6-PG (10). Probably 5% is converted
to G-1-P and about 10% is converted back to
glucose by the action of G-6-phosphatase (5).
In the psoriatic plaque, a 3 fold increase was
measured in the relative amount of the enzyme
TABLE XI
Results of histological examinations
Stratum
Total
Depth in p
Stratum
corneuni
depth in u.
Para-
keratosis
granulo-
sum—No.
of cell
layers
% of slide
having str.
gran.
No. of
suprapapil.
lary cell
layers
Approxi-
mate cell
volume ti*
Total cell
layers
Dermal
contami-
nation %
Pas Stain for Glycogen
Mrs. H.
Norm
Path.
Mr. I.
Norm
Path
Mr. S.
Norm
Path
Mrs. J.
Norm
Path
Mr. C.
Norm
Path
Mr. B.
Norm
Path
Mr. M.
Norm
Path
100
130
50
75
60
140
75
150
75
150
100
150
60
125
9
0%
75
90%
6
0%
20
5%
30
0%
65
50%
12
0%
20—100
35%
10
0%
55
50%
10
0%
75
100%
8
0%
25
50%
1
100%
2
10%
1
100%
2—3
95%
1.5
100%
2.5
50%
1
100%
2.5
65%
1
100%
3.5
80%
1
100%
1
10%
1
100%
1
50%
4
5
3
4
4
5
5
6
5
6
4
6
4
4
7
6
5
7
9
9
8
1300
3600
1200
1800
1200
2400
1300
3600
1300
2400
1300
2400
1200
2400
20
<5
10
5
5
<5
20
5
10
5
20
5
25
10
Basal layer—0
Midzone—50% & light
Basal layer—0
Midzone—90% and heavy
Basal Iayer—0
Midzone—10%
Basal layer—0
Midzone—10%
Basal layer—0
Midzone— <5%
Basal layer—0
Midzone— <5%
Basal—U
Midzone—0
Basal—U
Midzone—75% & heavy
Basal—0
Midzone—50% & light
Basal—0
Midzone—80% & heavy
Basal—0
Midzone—60% & moderate
Basal—0
Midzone—90% & heavy
Basal—0
Midzone—30% & light
Basal—0
Midzone—90% & heavy
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going to form 6-PG and a small, but significant
relative increase occurred in the enzyme re-
sponsible for G-1-P production.
(c) The Utilization of G-1-P to form
Glycogen and Uron-ic Acids
G-1-P was rapidly utilized and never
reached a measurable concentration. Although
the formation of G-1-P is probably increased
by about 70%, the increase in TJDPG PP
which utilized G-1-P was only 20%. If this
increase was not adequate to utilize all of the
G-1-P formed, G-1-P would build up within
the tissue. This did not occur and we must as-
sume that TJDPG PP is normally working
much below capacity and can therefore han-
dle the increased G-1-P turnover without a
large increase in the amount of enzyme pres-
ent.
Glycogen synthetase and TJDPG DII were
each increased by about 50%. Glycogen break-
down by phosphorylase was not significantly
increased and the level of glycogen within the
tissue therefore rose significantly. This in-
crease in tissue glycogen has been noted by
histochemical means previously (11). It is not a
sign of increased usage of glycogen for the
energy needs of the cell since the formation of
glucose-i-P from glycogen was not increased.
The increase in UDPG DII implies an in-
creased formation of mucopolysaccharides in
the psoriatic plaque. Increased uronic acids
and mucopolysaccharides have also been found
in psoriatic scale (12).
(d) The Formation of Pentose Sugars
(The Hexose Monophosphate Shunt)
The largest increases occurred in the two
enzymes (G-6-P DII and 6-PG DII) con-
cerned with the transformation of G-6-P into
5-carbon sugar phosphates. Weber has found
increased amounts of G-6-P DII in the serum of
patients with psoriasis (13).
This pathway provides the ribose-5-P
needed for nucleic acid synthesis and would
thus be expected to be a measure of DNA and
RNA synthesis. Psoriatic scales have increased
amounts of nucleic acids and of nucleic acid
breakdown products. From the data of Wheat-
ley (14) and of Hodgson (15) more pentoses
and nucleic acid precursors are produced than
can be utilized in nucleic acid formation. This
TABLE XII
Results of individual enzyme assays on epidermis of
normal people. Conditions as in table VI
Enzyme
20—25 year old normal
male Caucasians—
back
Mr. H.
Age 60—
Cau.—
Arm
Mr. M.
Age 54—
Cau.—
Shoulder
ilK 1.49 0.32 (10) 1.77 1.40
PGM 1.01 0.25 (9) 0.95 0.45
UDPG PP 0.66 0.01 (3) 0.75
UDPG DII 0.05 0.02 (11) 0.019 0.010
Gly Syn 0.20 0.02 (4) 0.075 0.050
P-ase 0.36 0.11 (8) 0.423 0.263
PHI 12.2 3.3 (7) 75.0 19.00
PFK 0.50 0.50
ALD 0.75 0.40
TIM 270 175
GDH 0.30 0.10
G-A-3P DII 11.5 5.00
PGK 10.0 11.5
PGIyM 28.7
EN 20.0
PK 0.80
LDH 36.0 14.7 (11) 81.3 40.0
ME 0.530 0.140
MDII 30.2 22.4 (6) 66.1 42.5
ICDH 1.65 0.23 (3) 1.65 1.00
G-6-P DII 1.21 0.23 (10) 1.90 0.90
6-P G DII 0.36 0.07 0.62 0.21
pathway then seems to be an exception to the
general rule of fine control of enzyme sys-
tems. It seems to produce more than is needed
and gives the first evidence of a perhaps faulty
control mechanism.
Many other intermediates are formed in
the reactions involved in the hexose mono-
phosphate shunt. Some of the G-6-P which
has been channeled into this shunt may be
transformed back into fructose-6-P and glycer-
aldehyde-3-P. The large increases in the
amount of hexose monophosphate shunt ac-
tivity which are present in the psoriatic plaque
may make this route a significant factor. We
believe there is good evidence for this view in
the changes in those enzymes concerned with
fructose-6-P and glyceraldehyde-3-P metabo-
lism as will be discussed below.
(e) The Utilization of Fructose-6-P and
the Formation of Triose Phosphates
Fructose-6-P is formed from G-6-P by the
action of PHI. This enzyme was increased 45%
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Pie. 2. Metabolic map showing altered metabolic pattern in involved epidermis of pa-
tients with psoriasis. The width of the arrows is proportional to the percentage increase of
each particular enzyme. Enzymes not assayed are shown by broken arrows.
in the psoriatic plaque. The activity of PHI is
10 x higher than the other enzymes which
are competing for the available G-6-P and
the great majority of G-6-P metabolized goes
through this pathway to F-6-P formation. The
relative increases of the other enzymes utiliz-
ing G-6-P were, however, greater than the in-
crease in PHI.
F-6-P is converted to F-i, 6-diP by PFK.
The activity of this enzyme was quite low
and in the non-involved skin may be working
at capacity. In one specimen of normal ap-
pearing epidermis, a measurable quantity of
F-6-P was present. This would imply that
PFK in this individual was not phosphorylating
all of the F-6-P presented to it and was there-
fore acting as a rate controlling enzyme for all
subsequent enzymatic steps.
PFK activity was increased 124% in the
psoriatic plaque. Since PHI, which forms F-6-P
from G-6-P, was increased by only 45% this
suggests that F-6-P is also being formed by
other routes.
One of these routes would be by fructose-6-P
formation from G-6-P after it had traversed
the hexose monophosphate shunt. If such a
mechanism were operating more glyceralde-
hyde-3-P would also be formed (the other
common substrate between the hexose mono-
phosphate shunt and the glycolytic route). The
enzyme aldolase interconverts F-i, 6-diP and
glyceraldehyde-3-P. A large increase in this en-
zyme would be expected under the above sup-
position since not only would one substrate
(F-1,6-diP) be increased by 124%, but also
the other substrate (glyceraldehyde-3-P) would
increase. An increase in aldolase activity of
241% was found. A similar increase has been
found by Comaish (3). This lends strong sup-
port to the idea that additional fructose-6-P and
glyceraldehyde-3-P formation through the hex-
ose monophosphate shunt is occurring.
Another possible mechanism leading to extra
F-6-P formation is by reversal of the forma-
tion of F-i, 6-diP from F-6-P. Fructose 1, 6-diP
formation from F-6-P by PFK is irreversible
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and the reverse reaction requires another en-
zyme. This enzyme, fructose-i ,6-diphosphatase,
is present in liver and kidney. It is a neces-
sary enzyme for the formation of glucose from
lactate, pyruvate, amino acids, etc. (gluconeo-
genesis).
Table XIII lists the results of our assays for
this enzyme. These data indicate that normally
10—20% of the F-i, 6-diP formed from F-6-P
by PFK is broken down by F-i, 6-diphospha-
tase to reform F-6-P. In the psoriatic plaque
this porportion is at least this high.
The possibility of complete recycling by a
mechanism such as that shown in Figure 3
must now be considered as quite likely since all
the necessary enzymes have been demonstrated.
TABLE XIII
Results of assays for fructose-i ,6-diphosphatase.
Condlions as in table VI
Rate of fructose-6-phosphate formation from
fructose-i, 6-diphosphate measured.
Normal
Psoriasis
Normal appearing Involved
.03
.08
.05
.112
.05 .200
glucose -6-P
This recycling would lead to the formation of
even greater amounts of five carbon sugars.
F-i ,6-diP reaches a measurable concentration
and the activity of aldolase which is also
quite low may again be a limiting step in carbo-
hydrate metabolism.
Hasegawa has suggested that in the psoriatie
plaque PFK is inhibited by G-6-P (4). This
seems quite unlikely since G-6-P is present in
very small amounts within the tissue. Two
attempts to demonstrate an inhibiting effect of
G-6-P upon the PFK reaction have been un-
successful even when amounts of G-6-P equal
to the natural substrate for the reaction (F-6-
P) were added.
(f) Pyruvate Formation and Utilization
The enzymes carrying out the trisephosphate
transformations from glyceraldehyde-3-P to
phosphoenolpyruvate were moderately increased
in accordance with the general increase in
glucose utilization. None of the intermediate
compounds build up to significant levels within
the tissue until PEP is reached and this com-
pound is present in low concentrations.
Pyruvate formation from PEP by PK is in-
creased slightly. This enzymatic reaction is a
very slow one and is probably working at near
maximum in the normal appearing tissue.
GLUCOSE-6-P dehya'rogenose 6-PHOSPHOGLIJCONATE
phosphohexbse 6-p/iospl,ogluconc/e
isomerose dehyc/rogenuse
RIBULOSE-5-P
I RIBOSE-5-PJ
Fia. 3. Proposed recycling of glucose through the hexose monophosphates shunt and
back into the glycolytie reaction sequence. The direction of the glycolytic reactions from
glucose-6-P to glyceraldehyde-3-P is reversed. This scheme is dependent upon fructose-i ,6-
diphosphatase which reverses the irreversible formation of fructose-i ,6-diphosphate by
phosphofructokinase.
FRUCT(
fructose -1,6
.diphosp/i of use
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PHOP HO EN OLPYRU VAlE
pyrovate
kinase
PYRUVATE+ —
pyPL/Vc7
mci/c ccroxy/cse\
enjynie
MALATE OXALOACETATE
lehydrogenase
Fia. 4. Proposed routes of pyruvate formation
from phosphoenolpyruvate.
TABLE XIV
Results of assays for phosphoenolpyruvate
carboxykinase. Conditions as in table VI
Rate of oxaloacetate formation from phospho-
enolpyruvate measured.
Normal Exfoliative Psoriasis
9.0 14.2
In contrast to the minor increase in forma-
tion of pyruvate from PEP by PK is the large
increase in the utilization of pyruvate by LDH
(>100%). In addition, the formation of acetate
from pyruvate is presumably much increased
in the involved area since Herdenstam has
shown a six fold increase in fatty acid and sterol
formation in such tissue (9). Also, increased
amounts of pyruvate are being transformed into
alanine in the psoriatic plaque (9). These con-
siderations led us to the belief that the in-
crease in the PK reaction was totally inade-
quate to provide enough pyruvate for all the
reactions using pyruvate. We, therefore, have
explored other pathways which might be con-
cerned with pyruvate production from PEP.
Assays of malic enzyme and of malate de-
hydrogenase indicated increases of over 100%
in these enzymes in the psoriatic plaque. If a
reaction existed which transformed phospho-
enolpyruvate into oxaloacetate, a pathway by-
passing PK would be established in which at
least 2 of the 3 enzymes involved had signifi-
cant increases in the psoriatic plaque. This path-
way is shown by the double line arrows in
Figure 4.
Such an enzyme is found in liver (16) and
is called phosphoenolpyruvate carboxykinase.
This enzyme was found in both normal and
psoriatic epidermis (Table XIV). There are not
enough data to state whether or not the level
is increased in the psoriatic plaque, but from
the high activity this would seem to be a major
pathway of phosphoenolpyruvate metabolism.
A third pathway of pyruvate formation
would include the phosphoenolpyruvate car-
boxykinase reaction, but would then form
pyruvate directly from oxaloacetate. This path-
way is shown by the broken arrow in Figure 4.
It has also been demonstrated in liver and the
enzyme catalyzing the reaction is called pyru-
vate carboxylase. This reaction is of great
interest for two reasons: first because it by-
passes the very slow malic enzyme reaction
and, secondly because it is very dependent upon
the level of acetyl CoA present in the tissue
and may act as control mechanism (17). We
have not yet had the opportunity to study
this reaction.
(g) The Tricarboxylic Acid Cycle and
Oxygen Utilization
Our measurements of isocitric dehydrogenase
(one of the key reactions of the tricarboxylic
acid cycle) showed no significant increase. The
mitochondrial reactions responsible for oxida-
tive phosphorylation provide ATP for the cell
and their activity can be measured by the
amount of oxygen taken up by a tissue. In-
creased oxygen uptake by the involved epi-
dermis in psoriasis has been reported (9) and
it is difficult to understand how this can occur
without a rise in the level of isocitric dehy-
drogenase. This problem remains unresolved.
(h) The Role of the Cof actors NAD,
NADH, NADP and NADPH
We were unable to detect NADP in our
"acid extract." The level of NAD reported is
approximately the same as that reported by
Findlay (18) and no significant difference be-
tween the involved and non-involved epidermis
was detected. NADH and NADPH are highly
labile substances in acid solution and special
techniques have to be used to preserve these
substances for assay. In boiled extracts (10
mm. ® 100° C. pH 7.4) we were unable to
detect any NADH or NADPH. Recently
using a 1 minute boiling time pH 8.5 we
have been able to detect NADH at a level of
0.14 mtm/mg in one specimen. Again, there
was no detectable NADPH present. In view
of the low levels of several of these co-factors
phosphoenoipyruec/e
carboxyk/ncse
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it is very possible that they play an important
role in metabolism and perhaps a controlling
one.
(i) The Lactate Concentration
Despite a presumed 100% increase in the
amount of lactate being formed within the
plaque, the tissue concentration of this sub-
stance did not rise significantly. We conclude
from this that the diffusion of lactate from
the epidermal cell into the blood stream is
more efficient in the psoriatic plaque and pre-
vents a rise in tissue lactate.
(j) Histology
Table XI lists the observed differences in
these epidermal specimens. The keratome took
a deeper cut in the epidermal slice from the
psoriatic lesion than from normal appearing
skin despite keratome settings which in all
cases were 02 mm. Stratum corneum may
vary in the extent of parakeratosis from very
little to over 90% in the involved areas. This
material may account for up to 60% of some
slices and, at least in the case of glucose-6-
phosphate dehydrogenase, Weber found only
oth as much activity in the parakeratotic
scale as in epidermis (19). This lack of en-
zymatic activity in a significant percentage of
the psoriatic plaque specimens would tend to
give falsely low values.
Crude estimations of cell size showed that
psoriatic cells have a volume 2 to 3 times
greater than cells in normal appearing epi-
dermis. Similar conclusions were reached by
Herdenstam (9) by different measurements.
This implies that the involved psoriatic areas
contained ½ to as many cells per unit
weight when compared with the normal ap-
pearing skin of psoriatic patients. On a per cell
basis the psoriatic plaque would then have
2 to 3 times as large values as the ones we
report.
Contamination of our specimens with dermis
was unavoidable, and was rarely greater than
20%. This factor would lower both the values
for psoriatic plaque and normal appearing epi-
dermis since the dermis is metabolically in-
active compared to epidermis.
SUMMARY
All of the enzymes assayed for were present
in both the involved and non-involved epi-
dermis of patients with psoriasis. Furthermore,
comparison with the incomplete data on the
epidermis of normal people discloses no re-
markable quantitative difference in enzyme
levels between the epidermis of normal people
and the normal-appearing epidermis of pa-
tients with psoriasis. We must conclude that
there is no evidence from this study to support
a theory of the genetic lack or impaired func-
tion of any of the measured enzymes of glyco-
gen formation and glycolysis.
The overall changes in metabolic pattern
which exist in the psoriatic plaque as compared
with the normal-appearing skin are consistent
with a reorganization of the resources of the
cell in order to facilitate cellular reproduction.
This reorganization proceeds not by a change in
the levels of one or two key enzymes, but by
controlled and consistent changes in whole
series of enzymes responsible for specific
metabolic or synthetic functions.
Outstanding in this regard is the increased
flow of glucose along the hexose monophosphate
shunt to supply the pentose needed for
nucleic acid formation. It may be possible to
correlate the degree of cell proliferation with
the epidermal concentration of this enzyme in
other dermatological disorders as well as in
psoriasis.
Increased production of glycogen and uronic
acids can also be demonstrated in the psoriatic
plaque. The glycogen accumulation is due to a
lack of increase in its breakdown and cannot
be regarded as an energy source of any im-
portance.
A recycling mechanism whereby glucose is
funneled into the hexose monophosphate shunt
and then back into the glycolytic pathway at
the triose phosphate stage probably occurs in
both normal and psoriatic epidermis, but is
more prominent in the psoriatic. Fructose-i ,6-
diphosphatase is a necessary enzyme for the
reversal of glycolysis from the triose phosphate
stage back to glucose-6-phosphate.
Pyruvate formation in the epidermis is un-
doubtedly much more complicated than has
been thought and the existence of at least two
pathways for the production of this compound
have been demonstrated.
The measured increases in enzyme activity in
the involved epidermis of patients with psoria-
sis have probably been underestimated in our
studies because of the inclusion of large amounts
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of parakeratotic and orthokeratotic material
in the psoriatic plaque slices. These structures
are probably much less active enzymatically
than a comparable weight of malpighiian cells.
Also, the malpighiian cells of the involved
epidermis are 2 to 3 times larger than the
cells of the normal looking areas, and on a per
cell basis their enzyme activities would again
be larger by this factor.
In conclusion attention must be shifted from
the enzyme levels themselves to the factors
which control the enzyme levels. And from
these factors to the proliferative stimulus which
in turn affects the controlling mechanisms and
allows or forces isolated areas of epidermis to
proliferate at such high rates.
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DISCUSSION
DR. Juiri HASEGAWA: First of all I want to
express my admiration for the work that was
presented here. I am a little envious of man-
power and the know-how which Dr. Haiprin
commands. I noticed in the diagram that the
enzyme from fructose-6 phosphate to fructose
1-6, diphosphate is indicated by a single arrow.
The enzyme in the downward direction is
mediated by phospho-fructosekinase and this
is not a reversible reaction. The enzyme reac-
tion in the reverse direction is fructose 1-6
diphosphatase. There doesn't have to be any
deficiency of enzyme in this area. A difference
in the enzyme content, the ratio between these
two enzymes can induce a tremendous change
in the cycling of the pentose shunt and is suffi-
cient to account for much of the observed data
in psoriasis. I would like to ask one question,
and that is, does Dr. Haiprin have enzyme
ratios between these two in psoriatic tissues?
Da. STANLEY I. CULLEN, Miami, Florida: I
would like to ask Dr. Halprin if he has any
comparisons in any of his enzyme studies be-
tween either the normal-appearing skin of the
psoriatic or the psoriatic plaque and non-
psoriatic individuals? I think this would be of
some importance.
DR. HALPRIN (in closing): In answer to the
second question first, the data in the paper on
the epidermis of normal people, both medical
students age 20 to 25 and a few elderly pa-
tients show no difference from the non-involved
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epidermis of patients with psoriasis. Dr.
Hasegawa is referring to the fact that the
formation of the fructose 1-6 diphosphate from
fructose 6 phosphate by phosphofructokinase is
an irreversible reaction. It is one of the key
reactions in glycolysis because in order to make
glucose from lactate, amino acid, or fats, you
must reverse the reaction. Any tissue that
makes glucose, like the kidney, must possess an
enzyme to reverse the formation of fructose
1,6 diphosphate. The enzyme which reverses
this reaction is fructose 1,6 diphosphatase. We
have measured this reaction and its activity is
20% of the phosphofructokinase reaction. In
other words, of the fructose-6-P which is con-
verted to fructose 1,6 diphosphate by phospho-
fruetokinase, 20 per cent is turned backwards
by fructose 1,6 diphosphatase. This seems to
be the same in the normal epidermis and
psoriatic plaque, although the activity of the
enzymes in both directions is increased in the
psoriatic plaque. I would like to make one
further comment; Dr. Hasegawa has recently
suggested that glucose-6-phosphate is an in-
hibitor of phosphofructokinase and that an
accumulation of the glucose-6-phosphate in the
psoriatic epidermis may inhibit this reaction
in the psoriatic and so interfere with glycolysis.
We have attempted to demonstrate this di-
rectly on two occasions and can demonstrate no
inhibition of this reaction by glucose-6 phos-
phate. In both the normal and psoriatic plaque
this reaction seems to work perfectly normally.
